Pulmonx Co. (NASDAQ:LUNG) Receives $12.75 Consensus Target Price from Brokerages

Shares of Pulmonx Co. (NASDAQ:LUNG) have been given an average recommendation of “Moderate Buy” by the six brokerages that are covering the firm, Marketbeat reports. Two research analysts have rated the stock with a hold recommendation and four have given a buy recommendation to the company. The average 12 month target price among brokerages that have issued ratings on the stock in the last year is $12.75.

A number of equities analysts have issued reports on LUNG shares. Stifel Nicolaus lowered their target price on Pulmonx from $17.00 to $16.00 and set a “buy” rating for the company in a report on Thursday, October 31st. Wells Fargo & Company cut their target price on shares of Pulmonx from $10.00 to $8.00 and set an “equal weight” rating for the company in a research note on Wednesday, December 11th. Finally, Citigroup restated a “neutral” rating and set a $7.50 price objective (down from $17.00) on shares of Pulmonx in a research report on Wednesday, December 11th.

Pulmonx Trading Down 2.2 %

NASDAQ:LUNG opened at $6.26 on Friday. The stock’s fifty day moving average price is $6.48 and its two-hundred day moving average price is $6.88. Pulmonx has a 52-week low of $5.46 and a 52-week high of $14.84. The company has a quick ratio of 6.77, a current ratio of 7.70 and a debt-to-equity ratio of 0.40.

Pulmonx (NASDAQ:LUNG) last issued its earnings results on Wednesday, October 30th. The company reported ($0.36) EPS for the quarter, beating the consensus estimate of ($0.43) by $0.07. Pulmonx had a negative net margin of 72.01% and a negative return on equity of 53.88%. The company had revenue of $20.39 million during the quarter, compared to analysts’ expectations of $20.39 million. During the same quarter in the previous year, the company posted ($0.39) EPS. On average, research analysts forecast that Pulmonx will post -1.53 EPS for the current year.

Insider Buying and Selling at Pulmonx

In other news, Director Glendon E. French III sold 20,000 shares of Pulmonx stock in a transaction on Friday, November 22nd. The shares were sold at an average price of $6.63, for a total transaction of $132,600.00. Following the transaction, the director now owns 1,071,974 shares in the company, valued at approximately $7,107,187.62. The trade was a 1.83 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Geoffrey Beran Rose sold 4,376 shares of Pulmonx stock in a transaction on Monday, December 2nd. The stock was sold at an average price of $6.18, for a total transaction of $27,043.68. Following the transaction, the insider now owns 291,057 shares in the company, valued at approximately $1,798,732.26. This trade represents a 1.48 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 29,873 shares of company stock worth $193,670 over the last quarter. Corporate insiders own 5.70% of the company’s stock.

Hedge Funds Weigh In On Pulmonx

Hedge funds and other institutional investors have recently bought and sold shares of the company. 272 Capital LP bought a new stake in Pulmonx in the third quarter valued at $25,000. nVerses Capital LLC bought a new stake in shares of Pulmonx during the third quarter worth about $26,000. Point72 Asia Singapore Pte. Ltd. bought a new stake in shares of Pulmonx during the second quarter worth about $37,000. Hsbc Holdings PLC bought a new stake in shares of Pulmonx during the second quarter worth about $93,000. Finally, Mackenzie Financial Corp bought a new stake in shares of Pulmonx during the second quarter worth about $102,000. Institutional investors and hedge funds own 91.04% of the company’s stock.

Pulmonx Company Profile

Pulmonx Corporation, a commercial-stage medical technology company, provides minimally invasive devices for the treatment of chronic obstructive pulmonary diseases. The company offers Zephyr Endobronchial Valve, a solution for the treatment of patients with hyperinflation associated with severe emphysema; and Chartis Pulmonary Assessment System, a balloon catheter and console system with flow and pressure sensors that are used to assess the presence of collateral ventilation.